Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Shp2 (Src-homology 2 domain-containing phosphatase 2) was originally reported as an oncogene in kinds of solid tumors and hematologic malignancies.
|
28085101 |
2017 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Gain-of-function variants in some RAS-MAPK pathway genes, including PTPN11 and NRAS, are associated with RASopathies and/or acquired hematological malignancies, most notably juvenile myelomonocytic leukemia (JMML).
|
28098151 |
2017 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SHP2 has emerged as an attractive target for therapeutic targeting in hematological malignancies for its cell autonomous and microenvironmental effects.
|
28306669 |
2017 |
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PTPN11 oncogene encodes the cytoplasmic protein tyrosine phosphatase SHP2, which, through its role in multiple signaling pathways, promotes the progression of hematological malignancies and other cancers.
|
29089257 |
2017 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Germline and somatic mutations in PTPN11 are involved in Noonan syndrome (NS), LEOPARD syndrome (LS), and hematological malignancies, as well as several solid tumors.
|
25039348 |
2014 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We analyzed 77 samples from hematologic malignancies, identifying a somatic mutation in CBL (p.C381R) in one patient with T-ALL that was associated with a uniparental disomy at the CBL locus and a germline heterozygous mutation in one patient with JMML.
|
22591685 |
2012 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, the role of SHP-2 mutations in non-hematological malignancies remains obscure.
|
18223690 |
2008 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Somatic PTPN11 mutations contribute to leukemogenesis in children with hematologic malignancies including juvenile myelomonocytic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, and myelodysplasia.
|
18799937 |
2008 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data suggest that mutations of PTPN11 as well as RAS play a role in the pathogenesis of not only myeloid hematological malignancies but also a subset of RMS malignancies.
|
16518851 |
2006 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We recently demonstrated that acquired mutations in PTPN11 are a major event in JMML and occur with variable prevalence in children with other hematologic malignancies, including MDS.
|
15725481 |
2005 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fully characterizing the incidence and spectrum of PTPN11 mutations in hematologic malignancies, and in other forms of cancer, is an area of active investigation.
|
14676626 |
2004 |
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Somatic PTPN11 mutations are common in patients with juvenile myelomonocytic leukemia (JMML) and have been reported in some other hematologic malignancies.
|
15385933 |
2004 |